Compare · ABBV vs YMTX
ABBV vs YMTX
Side-by-side comparison of AbbVie Inc. (ABBV) and Yumanity Therapeutics Inc. (YMTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and YMTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV carries a market cap of $501.19B.
- ABBV has hit the wire 17 times in the past 4 weeks while YMTX has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 0 for YMTX).
- Company
- AbbVie Inc.
- Yumanity Therapeutics Inc.
- Price
- -
- -
- Market cap
- $501.19B
- -
- 1M return
- -0.38%
- -
- 1Y return
- +23.56%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2016
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Yumanity Therapeutics Inc.
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.
Latest ABBV
- AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
- EVP, CHIEF OPERATIONS OFFICER Azita Saleki exercised 23,935 shares at a strike of $61.36 and covered exercise/tax liability with 13,481 shares, increasing direct ownership by 5% to 208,248 units (SEC Form 4)
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
Latest YMTX
- SEC Form SC 13G filed by Yumanity Therapeutics Inc.
- SEC Form SC 13D/A filed by Yumanity Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Yumanity Therapeutics Inc. (Amendment)
- Yumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Yumanity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Yumanity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Bartoszek Raymond J. bought $9,950 worth of shares (2,250 units at $4.42), increasing direct ownership by 15% to 17,206 units (SEC Form 4)
- Philips Craig W. bought $9,812 worth of shares (3,000 units at $3.27), increasing direct ownership by 5% to 60,811 units (SEC Form 4)
- Iadonato Shawn bought $17,398 worth of shares (5,000 units at $3.48), increasing direct ownership by 0.75% to 675,230 units (SEC Form 4)
- SEC Form EFFECT filed by Yumanity Therapeutics Inc.